Peripheral blood progenitor cell grafts contain high levels of platelet-secreted mediators

被引:14
作者
Foss, B
Abrahamsen, JF
Bruserud, O
机构
[1] Univ Bergen, Inst Med, N-5021 Bergen, Norway
[2] Haukeland Univ Hosp, Blood Bank, N-5021 Bergen, Norway
关键词
D O I
10.1046/j.1537-2995.2001.41111431.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The cytokine network in peripheral blood progenitor cell (PB PC) grafts may affect hematopoietic reconstitution or the risk of postransplant relapse of malignant disorders through effects on normal progenitor cells or contaminating malignant cells. Whether thrombopoietin (TPO), SCF, and platelet-secreted mediators are parts of this network was investigated. STUDY DESIGN AND METHODS: Peripheral blood and PBPC plasma samples were collected consecutively from patients with malignant disorders who underwent PBPC harvest. Blood samples were collected immediately before and after apheresis. Patients underwent mobilization by chemotherapy plus G-CSF, except for one patient who received only G-CSF Plasma levels were also determined for healthy controls. RESULTS: PBPC grafts had greater levels of platelet-secreted platelet factor 4 (PF4), beta -thromboglobulin, and platelet-derived growth factor isoform AB, as compared with venous levels in patients and controls. Although platelet and PF4 levels in autografts were significantly correlated, the graft:blood ratio was higher for PF4 than for platelets. In both the patients' blood and the autografts, TPO levels were increased from the levels in normal controls. Blood and graft levels of SCF were within the normal range. CONCLUSION: The cytokine network of PBPC autografts includes increased levels of TPO and several platelet-derived mediators.
引用
收藏
页码:1431 / 1437
页数:7
相关论文
共 36 条
[1]   Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products [J].
Ageitos, AG ;
Varney, ML ;
Bierman, PJ ;
Vose, JM ;
Warkentin, PI ;
Talmadge, JE .
BONE MARROW TRANSPLANTATION, 1999, 23 (01) :63-69
[2]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[3]  
Bruserud O, 1997, PLATELETS, V8, P397
[4]   Autologous stem cell transplantation as post-remission therapy in adult acute myelogenous leukemia: Does platelet contamination of peripheral blood mobilized stem cell grafts influence the risk of leukemia relapse? [J].
Bruserud, O ;
Foss, B ;
Abrahamsen, JF ;
Gjertsen, BT ;
Ernst, P .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (04) :433-443
[5]   Cytokines, platelet production and hemostasis [J].
Burstein, SA .
PLATELETS, 1997, 8 (2-3) :93-104
[6]   PLATELET-DERIVED GROWTH-FACTOR PROMOTES PROLIFERATION OF ERYTHROPOIETIC PROGENITOR CELLS-INVITRO [J].
DAINIAK, N ;
DAVIES, G ;
KALMANTI, M ;
LAWLER, J ;
KULKARNI, V .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (05) :1206-1214
[7]   Optimization of peripheral flood stem cell mobilization [J].
Demirer, T ;
Buckner, CD ;
Bensinger, WI .
STEM CELLS, 1996, 14 (01) :106-116
[8]   Peripheral blood stem cell mobilization for high-dose chemotherapy [J].
Demirer, T ;
Bensinger, WI ;
Buckner, CD .
JOURNAL OF HEMATOTHERAPY, 1999, 8 (02) :103-113
[9]   THE VALUE OF FLOW CYTOMETRIC ANALYSIS OF PLATELET GLYCOPROTEIN EXPRESSION ON CD34(+) CELLS MEASURED UNDER CONDITIONS THAT PREVENT P-SELECTIN-MEDIATED BINDING OF PLATELETS [J].
DERCKSEN, MW ;
WEIMAR, IS ;
RICHEL, DJ ;
BRETONGORIUS, J ;
VAINCHENKER, W ;
SLAPERCORTENBACH, ICM ;
PINEDO, HM ;
VONDEMBORNE, AEGK ;
GERRITSEN, WR ;
VANDERSCHOOT, CE .
BLOOD, 1995, 86 (10) :3771-3782
[10]  
FILES JC, 1981, BLOOD, V58, P607